CClinicalTrials.gg
CompletedNCT01544569Updated May 18, 2016

Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors

An observational study in Kidney Cancer, sponsored by Children's Oncology Group. Completed. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2016-05-18.

Sponsored by Children's Oncology Group · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
50
Ages
Up to 1 Year
Sex
All
01

Study summary

RATIONALE: Studying samples of tissue from patients with rhabdoid tumors in the laboratory may help doctor learn more about changes that occur in DNA and identify genes related to cancer.

PURPOSE: This research trial studies biomarkers in samples from young patients with rhabdoid tumors.

Read the detailed description

OBJECTIVES:

  • To investigate the expression and function of transposons in 50 primary rhabdoid tumors.

OUTLINE: Freshly frozen rhabdoid tumors will be studied using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to establish the genomic location of transposons. Protein expression in rhabdoid tumor tissue microarrays is also analyzed.

02

Conditions studied

  • Kidney Cancer

Keywords

  • rhabdoid tumor of the kidney
03

In context

Kidney Neoplasms

956 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.

This study's planned enrollment of 50 is below the median of 218 across 216 observational studies indexed under Kidney Neoplasms.

Browse Kidney Neoplasms studies →

Lead sponsor

Children's Oncology Group is the lead sponsor of 436 studies on the registry; 34 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

rhabdoid tumors

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Freshly frozen rhabdoid tumors from either renal or extra-renal sites from children younger than 2 years of age
  • Clinical patient information (age, gender, comorbidities, tumor stage, size, pathology, therapy, outcome) available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • GeneticDNA analysis
  • Geneticfluorescence in situ hybridization
  • Geneticgene expression analysis
  • Geneticgene mapping
  • Geneticmicroarray analysis
  • Geneticpolymerase chain reaction
  • Geneticprotein expression analysis
  • Otherlaboratory biomarker analysis
  • Othermedical chart review
06

What researchers measure

Primary outcomes

  1. Expression and function of transposons in rhabdoid tumors

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01544569
Lead sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Mar 6, 2012
Start date
Mar 2012
Primary completion
May 2016
Last update
May 18, 2016

Study contacts

Elizabeth A. Mullen, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion